Complete financial analysis of Concert Pharmaceuticals, Inc. (CNCE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Concert Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Voestalpine AG (VAS.DE) Income Statement Analysis – Financial Results
- Focus Systems Corporation (4662.T) Income Statement Analysis – Financial Results
- Aichi Tokei Denki Co., Ltd. (7723.T) Income Statement Analysis – Financial Results
- General Accident PLC (GACB.L) Income Statement Analysis – Financial Results
- Cedar Woods Properties Limited (CWP.AX) Income Statement Analysis – Financial Results
Concert Pharmaceuticals, Inc. (CNCE)
About Concert Pharmaceuticals, Inc.
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 32.58M | 7.90M | 1.08M | 10.51M | 143.89M | 174.00K | 66.73M | 8.58M | 25.41M | 12.85M | 19.47M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 32.58M | 7.90M | 1.08M | 10.51M | 143.89M | 174.00K | 66.73M | 8.58M | 25.41M | 12.85M | 19.47M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 87.56M | 61.62M | 59.82M | 43.15M | 30.22M | 36.98M | 28.89M | 27.47M | 21.79M | 24.19M | 23.44M |
| General & Administrative | 22.25M | 18.62M | 19.97M | 22.94M | 21.02M | 14.36M | 13.06M | 11.70M | 8.03M | 7.27M | 7.38M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 22.25M | 18.62M | 19.97M | 22.94M | 21.02M | 14.36M | 13.06M | 11.70M | 8.03M | 7.27M | 7.38M |
| Other Expenses | 283.00K | 301.00K | 306.00K | 0.00 | 0.00 | 0.00 | 0.00 | 20.90M | 12.84M | 0.00 | 0.00 |
| Operating Expenses | 110.09M | 80.55M | 80.09M | 66.09M | 51.24M | 51.34M | 41.94M | 39.17M | 29.82M | 31.46M | 30.81M |
| Cost & Expenses | 110.09M | 80.55M | 80.09M | 66.09M | 51.24M | 51.34M | 41.94M | 39.17M | 29.82M | 31.46M | 30.81M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | -127.00K | 815.00K | 447.00K | 309.00K | 1.15M | 1.67M | 1.86M | 18.00K |
| Depreciation & Amortization | 4.02M | 3.81M | 827.00K | 1.25M | 1.01M | 893.00K | 785.00K | 1.05M | 1.35M | 1.45M | 1.62M |
| EBITDA | -73.49M | -68.84M | -78.19M | -54.46M | 97.16M | -49.83M | 25.70M | -29.50M | -3.04M | -17.14M | -9.68M |
| EBITDA Ratio | -225.57% | -871.15% | -7,259.80% | -518.46% | 67.52% | -28,636.21% | 38.51% | -343.95% | -11.98% | -133.36% | -49.74% |
| Operating Income | -77.51M | -72.65M | -79.02M | -55.58M | 92.65M | -51.17M | 24.79M | -30.60M | -4.41M | -18.61M | -11.35M |
| Operating Income Ratio | -237.92% | -919.35% | -7,336.58% | -529.12% | 64.39% | -29,406.32% | 37.15% | -356.79% | -17.36% | -144.84% | -58.28% |
| Total Other Income/Expenses | -2.54M | -2.20M | 849.00K | -127.00K | 2.69M | 447.00K | -185.00K | -1.10M | -1.65M | -1.83M | 26.00K |
| Income Before Tax | -80.05M | -74.85M | -78.17M | -55.71M | 95.34M | -50.72M | 24.60M | -31.70M | -6.06M | -20.44M | -11.32M |
| Income Before Tax Ratio | -245.72% | -947.24% | -7,257.75% | -530.33% | 66.26% | -29,149.43% | 36.87% | -369.62% | -23.84% | -159.11% | -58.15% |
| Income Tax Expense | 2.54M | -85.00K | -837.00K | 313.00K | -300.00K | 447.00K | 429.00K | 49.00K | 21.00K | 22.00K | 44.00K |
| Net Income | -82.59M | -74.77M | -77.33M | -56.02M | 95.64M | -50.72M | 24.17M | -31.70M | -6.06M | -20.44M | -11.32M |
| Net Income Ratio | -253.53% | -946.17% | -7,180.04% | -533.31% | 66.47% | -29,149.43% | 36.23% | -369.62% | -23.84% | -159.11% | -58.15% |
| EPS | -2.40 | -2.40 | -3.26 | -2.40 | 4.22 | -2.28 | 1.14 | -2.00 | -0.35 | -1.82 | -1.01 |
| EPS Diluted | -2.40 | -2.40 | -3.26 | -2.40 | 4.08 | -2.28 | 1.09 | -2.00 | -0.35 | -1.82 | -1.01 |
| Weighted Avg Shares Out | 34.41M | 31.20M | 23.74M | 23.37M | 22.64M | 22.23M | 21.15M | 15.84M | 17.22M | 11.21M | 11.21M |
| Weighted Avg Shares Out (Dil) | 34.41M | 31.20M | 23.74M | 23.37M | 23.44M | 22.23M | 22.27M | 15.84M | 17.22M | 11.21M | 11.21M |
Concert Pharmaceuticals, Inc. (CNCE) Q3 2022 Earnings Call Transcript
Concert Pharmaceuticals, Inc. (NASDAQ:CNCE ) Q3 2022 Earnings Conference Call November 7, 2022 8:30 AM ET Company Participants Justine Koenigsberg - Senior Vice President, Corporate Communications and Investor Relation Roger Tung - President and Chief Executive Officer Marc Becker -...
Concert Pharmaceuticals (CNCE) Reports Q3 Loss, Misses Revenue Estimates
Concert (CNCE) delivered earnings and revenue surprises of 1.69% and 97.58%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Concert Pharmaceuticals Reports Third Quarter 2022 Financial Results
LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the third quarter of 2022. “With the THRIVE-AA clinical program completed and positive Phase 3 results in hand for deuruxolitinib in alopecia areata, we are well on our...
Concert Pharmaceuticals to Report Third Quarter 2022 Results on November 7, 2022
LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the third quarter of 2022, on Monday, November 7, 2022, before the U.S. financial markets open. The Company will host a conference call...
Concert Pharmaceuticals to Report Third Quarter 2022 Results on November 7, 2022
LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the third quarter of 2022, on Monday, November 7, 2022, before the U.S. financial markets open. The Company will host a conference call...
Concert Pharmaceuticals Announces Presentation of CTP-543 THRIVE-AA1 Phase 3 Data in Alopecia Areata During Late Breaking Session at EADV Congress
MILAN--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Dr. Brett King, Yale University School of Medicine, presents CTP-543 THRIVE-AA1 Phase 3 data during the EADV Late Breaking News Session.
Concert Pharmaceuticals Announces Presentation of CTP-543 THRIVE-AA1 Phase 3 Data in Alopecia Areata During Late Breaking Session at EADV Congress
MILAN--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the presentation of data from its Phase 3 clinical trial, THRIVE-AA1. The presentation highlights THRIVE-AA1 study results evaluating Concert’s oral investigational medicine CTP-543 in adult patients with moderate to severe alopecia areata,...
Source: https://incomestatements.info
Category: Stock Reports